[go: up one dir, main page]

WO1999050637A3 - Isolated multimeric complexes useful in analysis of t cells, peptides useful in making the complexes, and uses thereof - Google Patents

Isolated multimeric complexes useful in analysis of t cells, peptides useful in making the complexes, and uses thereof Download PDF

Info

Publication number
WO1999050637A3
WO1999050637A3 PCT/US1999/006615 US9906615W WO9950637A3 WO 1999050637 A3 WO1999050637 A3 WO 1999050637A3 US 9906615 W US9906615 W US 9906615W WO 9950637 A3 WO9950637 A3 WO 9950637A3
Authority
WO
WIPO (PCT)
Prior art keywords
complexes
useful
cells
analysis
making
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US1999/006615
Other languages
French (fr)
Other versions
WO1999050637A2 (en
WO1999050637A8 (en
Inventor
Pedro Romero
Rod Dunbar
Danila Valmori
Mikael Pittet
Daniel Speiser
Vincenzo Cerundolo
Graham Ogg
Jean-Charles Cerrotini
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Ludwig Institute for Cancer Research Ltd
University of Oxford
Ludwig Cancer Research
Original Assignee
Ludwig Institute for Cancer Research Ltd
University of Oxford
Ludwig Cancer Research
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ludwig Institute for Cancer Research Ltd, University of Oxford, Ludwig Cancer Research filed Critical Ludwig Institute for Cancer Research Ltd
Priority to AU33654/99A priority Critical patent/AU3365499A/en
Publication of WO1999050637A2 publication Critical patent/WO1999050637A2/en
Publication of WO1999050637A8 publication Critical patent/WO1999050637A8/en
Publication of WO1999050637A3 publication Critical patent/WO1999050637A3/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56966—Animal cells
    • G01N33/56977—HLA or MHC typing
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70539—MHC-molecules, e.g. HLA-molecules
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2815—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD8
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2851—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the lectin superfamily, e.g. CD23, CD72
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/289—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD45

Landscapes

  • Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Cell Biology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Virology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Pathology (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

The invention involves multicomponent complexes, which use useful in analysis of T cells. The complexes contain at least first and second binding partners, which bind to each other. The second binding partner engages a plurality of immune complexes, which comprise an NHC molecule, a β2 microglobulin molecule, and a peptide. Preferably, there are at least four of these immune complexes per multicomponent complex. These can be used to determine or to isolate cytolytic T cells.
PCT/US1999/006615 1998-03-27 1999-03-25 Isolated multimeric complexes useful in analysis of t cells, peptides useful in making the complexes, and uses thereof Ceased WO1999050637A2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU33654/99A AU3365499A (en) 1998-03-27 1999-03-25 Isolated multimeric complexes useful in analysis of t cells, peptides useful in making the complexes, and uses thereof

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US4985098A 1998-03-27 1998-03-27
US09/049,850 1998-03-27

Publications (3)

Publication Number Publication Date
WO1999050637A2 WO1999050637A2 (en) 1999-10-07
WO1999050637A8 WO1999050637A8 (en) 2000-01-06
WO1999050637A3 true WO1999050637A3 (en) 2000-04-13

Family

ID=21962080

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1999/006615 Ceased WO1999050637A2 (en) 1998-03-27 1999-03-25 Isolated multimeric complexes useful in analysis of t cells, peptides useful in making the complexes, and uses thereof

Country Status (2)

Country Link
AU (1) AU3365499A (en)
WO (1) WO1999050637A2 (en)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6458354B1 (en) 1996-03-28 2002-10-01 The Johns Hopkins University Molecular complexes which modify immune responses
NZ331688A (en) 1996-03-28 2000-02-28 Univ Johns Hopkins Soluble divalent and multivalent heterodimeric analogs of proteins
US6268411B1 (en) 1997-09-11 2001-07-31 The Johns Hopkins University Use of multivalent chimeric peptide-loaded, MHC/ig molecules to detect, activate or suppress antigen-specific T cell-dependent immune responses
FR2806727A1 (en) * 2000-03-23 2001-09-28 Pf Medicament MOLECULE OF PHARMACEUTICAL INTEREST COMPRISING IN THE N-TERMINAL END A GLUTAMIC ACID OR GLUTAMINE IN THE FORM OF A PHYSIOLOGICALLY ACCEPTABLE ACID ADDITION SALT
AU2001271273A1 (en) * 2000-05-24 2001-12-03 Ludwig Institute For Cancer Research Multicomponent conjugates which bind to target molecules and stimulate cell lysis
CA2440474A1 (en) 2001-04-05 2002-10-17 Virginia Mason Research Center Methods of mhc class ii epitope mapping, detection of autoimmune t cells and antigens, and autoimmune treatment
WO2009003492A1 (en) 2007-07-03 2009-01-08 Dako Denmark A/S Mhc multimers, methods for their generation, labeling and use
US7892559B2 (en) * 2002-01-30 2011-02-22 Survac Aps Survivin-derived peptides and use thereof
US20040072262A1 (en) 2002-10-11 2004-04-15 Montero-Julian Felix A. Methods and systems for detecting MHC class I binding peptides
EP1766393A4 (en) * 2004-05-07 2008-06-18 Beckman Coulter Inc Mhc bridging system for detecting ctl-mediated lysis of antigen presenting cells
EP2226332A1 (en) 2004-06-17 2010-09-08 Beckman Coulter, Inc. Mycobacterium tuberculosis epitopes and methods of use thereof
EP2361930A3 (en) 2007-03-26 2011-10-26 Dako Denmark A/S Multimers of MHC-peptide complexes and uses thereof in Borrelia infectious diseases
WO2009039854A2 (en) 2007-09-27 2009-04-02 Dako Denmark A/S Mhc multimers in tuberculosis diagnostics, vaccine and therapeutics
DK2254592T3 (en) 2008-02-28 2019-09-09 Dako Denmark As MHC multimers for Borrelia diagnostics and disease
WO2010009735A2 (en) 2008-07-23 2010-01-28 Dako Denmark A/S Combinatorial analysis and repair
GB0817244D0 (en) 2008-09-20 2008-10-29 Univ Cardiff Use of a protein kinase inhibitor to detect immune cells, such as T cells
WO2010037402A1 (en) 2008-10-02 2010-04-08 Dako Denmark A/S Molecular vaccines for infectious disease
US11992518B2 (en) 2008-10-02 2024-05-28 Agilent Technologies, Inc. Molecular vaccines for infectious disease
US12258373B2 (en) 2018-12-17 2025-03-25 Immudex Aps Panel comprising Borrelia MHC multimers

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
DUNBAR R.: "Characterization of Human Cytotoxic T-Lymphocyte (CTL) Responses to Tumor Antigens using fluorogenic MHC Class I/Peptide complexes", TUMOR IMMUNOLOGY, vol. 92, December 1997 (1997-12-01), pages 12, SEE ABSTRACT NO. 3.3, XP002923255 *

Also Published As

Publication number Publication date
WO1999050637A2 (en) 1999-10-07
AU3365499A (en) 1999-10-18
WO1999050637A8 (en) 2000-01-06

Similar Documents

Publication Publication Date Title
WO1999050637A8 (en) Isolated multimeric complexes useful in analysis of t cells, peptides useful in making the complexes, and uses thereof
EP2360259A3 (en) Promyostatin peptides and methods of using same
EP1526141A3 (en) MHC complexes and uses thereof
EP2141243A3 (en) Protein scaffolds for antibody mimics and other binding proteins
EP3196213A3 (en) Antibodies directed to her-3 and uses thereof
ATE387458T1 (en) FAS ANTIGEN BINDING LIGAND
EP2284180A3 (en) Peptides that specifically bind HGF receptor (CMET) and uses thereof
NO20000086L (en) Chimerically soluble interleukin-6 receptor / ligand protein, and analogues and applications thereof
CA2413156A1 (en) Expression vectors
HUP0301812A2 (en) Screening method
CA2302147A1 (en) Methods for protein screening
BR0309279A (en) Multilayer macromolecules and methods for using them
EP1005539A4 (en) IKK-$g(a) PROTEINS, NUCLEIC ACIDS AND METHODS
WO1998057983A3 (en) Mammalian neuro-growth factor like protein
WO2004018619A3 (en) P53 binding t cell receptor molecules and uses thereof
WO2001094949A3 (en) Soluble cd1 compositions and uses thereof
EP2292638A3 (en) MAGE-C2 antigenic peptides and uses thereof
WO2001085779A3 (en) Protein complexes and assays for screening anti-cancer agents
WO2004096156A3 (en) Toll-like receptor 9 effector agents and uses thereof
EP0352228A3 (en) Novel proteins
EP0372503A3 (en) Anticoagulant peptides
WO2002026778A3 (en) Isolated peptides which bind to hla-c molecules and uses thereof
AU5924699A (en) Methods for identifying hot-spot residues of binding proteins and small compounds that bind to the same
EP0885959A3 (en) Human Wnt-5b protein
CA2112701A1 (en) Proteins s polypeptides and uses thereof

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AU CA JP

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE

121 Ep: the epo has been informed by wipo that ep was designated in this application
AK Designated states

Kind code of ref document: C1

Designated state(s): AU CA JP

AL Designated countries for regional patents

Kind code of ref document: C1

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE

CFP Corrected version of a pamphlet front page
CR1 Correction of entry in section i
AK Designated states

Kind code of ref document: A3

Designated state(s): AU CA JP

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
122 Ep: pct application non-entry in european phase